Tina Wang

Tina Wang

Auto-generated profile, based on publicly available information

Tina Wang

Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
NBNam Bui
Nam Bui
JHJustin K. Huang
Justin K. Huang
ABAna Bojorquez-Gomez
Ana Bojorquez-Gomez
KLKatherine Licon
Katherine Licon
KSKyle S. Sanchez
Kyle S. Sanchez
TITrey Ideker
Trey Ideker
Human papillomavirus (HPV)–negative head and neck squamous cell carcinoma (HNSCC) represents a distinct classification of cancer with worse expected outcomes. Of the 11 genes recurrently mutated in HNSCC, we identify a singular and substantial survival advantage for mutations in the gene encoding Nuclear Set Domain Containing Protein 1 (NSD1), a histone methyltransferase altered in approximately 10% of patients. This effect, a 55% decrease in risk of death in NSD1-mutated versus non-mutated patients, can be validated in an independent cohort. NSD1 alterations are strongly associated with widespread genome hypomethylation in the same tumors, to a degree not observed for any other mutated gene. To address whether NSD1 plays a causal role in these associations, we use CRISPR-Cas9 to disrupt NSD1 in HNSCC cell lines and find that this leads to substantial CpG hypomethylation and sensitivity to cisplatin, a standard chemotherapy in head and neck cancer, with a 40% to 50% decrease in the IC50 value. Such results are reinforced by a survey of 1,001 cancer cell lines, in which loss-of-function NSD1 mutations have an average 23% decrease in cisplatin IC50 value compared with cell lines with wild-type NSD1.Significance: This study identifies a favorable subtype of HPV–negative HNSCC linked to NSD1 mutation, hypomethylation, and cisplatin sensitivity. Mol Cancer Ther; 17(7); 1585–94. ©2018 AACR.

15 December 2022 in Aging
Verified
Journal Article
Open access
PDF file
MSMikki Schantell
Mikki Schantell
BTBrittany K. Taylor
Brittany K. Taylor
RSRachel K. Spooner
Rachel K. Spooner
PMPamela E. May
Pamela E. May
JOJennifer O’nEill
Jennifer O’nEill
TWTony W. Wilson
Tony W. Wilson
Background: Despite effective antiretroviral therapy, cognitive impairment and other aging-related comorbidities are more prevalent in people with HIV (PWH) than in the general population. Previous research examining DNA methylation has shown PWH exhibit accelerated biological aging. However, it is unclear how accelerated biological aging may affect neural oscillatory activity in virally suppressed PWH, and more broadly how such aberrant neural activity may impact neuropsychological performance. Methods: In the present study, participants (n = 134) between the ages of 23 – 72 years underwent a neuropsychological assessment, a blood draw to determine biological age via DNA methylation, and a visuospatial processing task during magnetoencephalography (MEG). Our analyses focused on the relationship between biological age and oscillatory theta (4-8 Hz) and alpha (10 - 16 Hz) activity among PWH (n=65) and seronegative controls (n = 69). Results: PWH had significantly elevated biological age when controlling for chronological age relative to controls. Biological age was differentially associated with theta oscillations in the left posterior cingulate cortex (PCC) and with alpha oscillations in the right medial prefrontal cortex (mPFC) among PWH and seronegative controls. Stronger alpha oscillations in the mPFC were associated with lower CD4 nadir and lower current CD4 counts, suggesting such responses were compensatory. Participants who were on combination antiretroviral therapy for longer had weaker theta oscillations in the PCC. Conclusions: These findings support the concept of interactions between biological aging and HIV status on the neural oscillatory dynamics serving visuospatial processing. Future work should elucidate the long-term trajectory and impact of accelerated aging on neural oscillatory dynamics in PWH.

4 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
TWTina Wang
Tina Wang
AMand Ma
and Ma
AHAndrew N. Hogan
Andrew N. Hogan
SFSamson Fong
Samson Fong
KLKatherine Licon
Katherine Licon
TITrey Ideker
Trey Ideker
SUMMARY: Mammals progress through similar physiological stages during life, from early development to puberty, aging, and death. Yet, the extent to which this conserved physiology reflects conserved molecular events is unclear. Here, we map common epigenetic changes experienced by mammalian genomes as they age, focusing on evolutionary comparisons of humans to dogs, an emerging model of aging. Using targeted sequencing, we characterize the methylomes of 104 Labrador retrievers spanning a 16 year age range, achieving >150X coverage within mammalian syntenic blocks. Comparison with human methylomes reveals a nonlinear relationship which translates dog to human years, aligns the timing of major physiological milestones between the two species, and extends to mice. Conserved changes center on specific developmental gene networks which are sufficient to capture the effects of anti-aging interventions in multiple mammals. These results establish methylation not only as a diagnostic age readout but as a cross-species translator of physiological aging milestones.

3 April 2023
Verified
Other
Open access
MHMelody S. Hsu
Melody S. Hsu
SSShaina Sedighim
Shaina Sedighim
TWTina Wang
Tina Wang
JAJoseph Antonios
Joseph Antonios
RERichard G. Everson
Richard G. Everson
RPRobert M. Prins
Robert M. Prins

3 April 2023
Verified
Other
Open access
MHMelody S. Hsu
Melody S. Hsu
SSShaina Sedighim
Shaina Sedighim
TWTina Wang
Tina Wang
JAJoseph Antonios
Joseph Antonios
RERichard G. Everson
Richard G. Everson
RPRobert M. Prins
Robert M. Prins
Although immunotherapeutic strategies are emerging as adjunctive treatments for cancer, sensitive methods of monitoring the immune response after treatment remain to be established. We used a novel next-generation sequencing approach to determine whether quantitative assessments of tumor-infiltrating lymphocyte (TIL) content and the degree of overlap of T-cell receptor (TCR) sequences in brain tumors and peripheral blood were predictors of immune response and overall survival in glioblastoma patients treated with autologous tumor lysate–pulsed dendritic cell immunotherapy. A statistically significant correlation was found between a higher estimated TIL content and increased time to progression and overall survival. In addition, we were able to assess the proportion of shared TCR sequences between tumor and peripheral blood at time points before and after therapy, and found the level of TCR overlap to correlate with survival outcomes. Higher degrees of overlap, or the development of an increased overlap following immunotherapy, was correlated with improved clinical outcome, and may provide insights into the successful, antigen-specific immune response. Cancer Immunol Res; 4(5); 412–8. ©2016 AACR.

3 April 2023
Verified
Other
Open access
MHMelody S. Hsu
Melody S. Hsu
SSShaina Sedighim
Shaina Sedighim
TWTina Wang
Tina Wang
JAJoseph Antonios
Joseph Antonios
RERichard G. Everson
Richard G. Everson
RPRobert M. Prins
Robert M. Prins
Supplementary Figure 3 has the top 25 TCR clones from tumor biopsies at pre-treatment and the frequency of these clones in the blood.